Please login to the form below
Glybera
This page shows the latest Glybera news and features for those working in and with pharma, biotech and healthcare.
AZ makes gene therapy move with 4DMT alliance
While enormously exciting gene therapy is still very much in its infancy, with just three commercial gene therapies approved in Europe and the US since UniQure’s Glybera made its debut
Latest news
-
UniQure’s starts pivotal haemophilia B gene therapy trial
UniQure has the distinction of being the first company to get approval for a gene therapy in Europe, winning a green light for its Glybera (alipogene tiparvovec) product for the
-
Plasticell and London’s gene therapy pioneers to tackle manufacturing conundrum
Another gene therapy, UniQure’s Glybera, was withdrawn from the market after it flopped commercially – in part because of the excessive cost of manufacturing it.
-
NICE backs GSK’s €594k gene therapy for rare disease
Strimvelis was approved by the EMA in 2016 - the second gene therapy to get a green light anywhere in the world after UniQure’s $1m Glybera (alipogene tiparvovec) product for lipoprotein
-
Spark’s Luxturna becomes US’s first approved gene therapy
UniQure charged $1m for its Glybera (alipogene tiparvovec) product for lipoprotein lipase deficiency (LPLD) - the first gene therapy approved in Europe - but that product was withdrawn from the market this year
-
Spark closes on first US gene therapy approval
The first (and so far only) gene therapy to reach the market in the EU - UniQure/Chiesi's 1m-per-treatment Glybera (alipogene tiparvovec) for lipoprotein lipase deficiency (LPLD) - was withdrawn
More from news
Approximately 4 fully matching, plus 16 partially matching documents found.
Latest Intelligence
-
Bluebird Bio: on the cusp of a gene therapy revolution
success. Europe has already seen two gene therapies approved but fail commercially – UniQure’s Glybera and GSK’s Strimvelis – and so Bluebird has to learn lessons on pricing and reimbursement and ... That means gene products hitting that Glybera
-
Health on instalment
Before being pulled from the European market for safety concerns and lack of uptake, pancreatic drug Glybera cost $1m a dose.
-
Rare diseases: meeting the challenge
Glybera, the expensive gene therapy developed for a small subset of patients with the rare familial lipoprotein lipase deficiency (LPLD). ... The company’s chief executive Matthew Kapusta said simply: “Glybera’s usage has been extremely limited and
-
Pharma deals in April 2015
Following Glybera's approval in Europe for lipoprotein lipase deficiency (LPLD), uniQure, the gene therapy pioneer has announced an exclusive strategic collaboration with Bristol Myers Squibb (BMS) for its lead candidate ... Glybera's $1m cost per
-
Anticipating the future in healthcare
As a gene therapy, Glybera is injected through a one-time course of up to 60 consecutive intramuscular injections. ... The introduction of therapies such as Glybera and Holostem will have significant implications on the healthcare ecosystem.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest appointments
-
Basilea's Hans Christian Rohde takes up commercial role at uniQure
In his new role at Netherlands-based uniQure he will be tasked with helping the company commercialise Glybera, which last month became the first gene therapy to be approved in the ... Glybera treats patients with the inherited disease lipoprotein lipase
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
The gene therapy revolution
There has already been one notable disappointment. In 2017 uniQure pulled its gene therapy, Glybera (alipogene tiparvovec) for the rare inherited disorder lipoprotein lipase deficiency (LPLD) from Europe after 5 years,
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Account Executive/ Senior Account Executive
-
competitive Salary Offfered
- Account Manager- Healthcare Advertising
-
Negotiable
-
Associate Director
-
£75, 000-90, 000
-
Account Manager / Account Director
-
Competative
-
Medical Writer
-
Bonus Scheme, PTO &Private Healthcare
-
Experienced Medical Writers
-
Competitive Salary and Benefits
-
Senior Account Manager
-
Competitive Salary Offered
- Senior Account Executive with progression to Account Manager, Me...
-
Excellent package
-
Business Director
-
Competitive Salary Offered
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Principal Health Economist - North-West
-
Negotiable
-
Account Manager
-
Negotiable
-
Systematic Reviewer - Oxford
-
Negotiable
- Business Development Director – Health Education
-
excellent commission
Subscribe to our email news alerts
- Industry frustrated by late warning on 'no deal' Brexit disruption
- UK’s genomics leadership attracts IQVIA investment, regardless of Brexit
- Lucid Group celebrate another magical year at their Winter Meeting
- Biogen picks up another drug from wide-ranging Ionis alliance
- As France protests, Sanofi takes axe to 670 jobs
- Leicester NHS Trust’s staff intranet is integral to HCPs’ working day
PMHub
Complete Medical Communications (CMC)
CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...
Latest intelligence
- Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
- What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
- What everyone forgets about good organisational change in pharma
- Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
- Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
- Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...
Quick links
Infographics
